Journal
ACTA PHARMACEUTICA SINICA B
Volume 11, Issue 10, Pages 3060-3091Publisher
INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2021.04.023
Keywords
Acute respiratory distress syndrome; Nanomedicine; Anti-inflammatory therapy; Drug delivery; Targeting strategy; Acute lung injury; COVID-19; Pathophysiologic feature
Categories
Funding
- National Natural Science Foundation of China [81872810]
- Program for HUST Academic Frontier Youth Team (China) [2018QYTD13]
- Fundamental Research Funds for the Central Universities (China) [2018KFYYXJJ019, 2019KFYRCPY049]
Ask authors/readers for more resources
Nanomedicine has shown unique advantages in ARDS therapy by interacting with inflammatory cells through targeted delivery, reversing abnormal changes, and demonstrating good therapeutic effects while reducing toxicity.
Acute respiratory distress syndrome (ARDS) is characterized by the severe inflammation and destruction of the lung air-blood barrier, leading to irreversible and substantial respiratory function dam -age. Patients with coronavirus disease 2019 (COVID-19) have been encountered with a high risk of ARDS, underscoring the urgency for exploiting effective therapy. However, proper medications for ARDS are still lacking due to poor pharmacokinetics, non-specific side effects, inability to surmount pulmonary barrier, and inadequate management of heterogeneity. The increased lung permeability in the pathological environment of ARDS may contribute to nanoparticle-mediated passive targeting delivery. Nanomedicine has demonstrated unique advantages in solving the dilemma of ARDS drug therapy, which can address the shortcomings and limitations of traditional anti-inflammatory or antioxidant drug treatment. Through passive, active, or physicochemical targeting, nanocarriers can interact with lung epithelium/endothelium and inflammatory cells to reverse abnormal changes and restore homeostasis of the pulmonary environment, thereby showing good therapeutic activity and reduced toxicity. This article reviews the latest applications of nanomedicine in pre-clinical ARDS therapy, highlights the strategies for targeted treatment of lung inflammation, presents the innovative drug delivery systems, and provides inspiration for strengthening the therapeutic effect of nanomedicine-based treatment. (C) 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available